The C-X-C motif chemokine receptor 4 (CXCR4)/C-X-C motif chemokine ligand 12 (CXCL12) axis drives immune exclusion in pancreatic ductal adenocarcinoma (PDA). Building on our preclinical data, we conducted the first stage of an open-label, single-arm phase 2 clinical trial combining CXCR4 inhibition (motixafortide), PD-...
A. Raufi, Edridge K. D'Souza, Michael S. May et al.· Nature Communications· 0 citations
Findings support continued evaluation of ACT as a strategy to enhance chemotherapy delivery and improve outcomes in borderline resectable or LAPC, and show no apparent effect on the expected safety profile of mFOLFIRINOX.
Erin Pierce, Ragnar Bendiksen, Amir Snapir et al.· Cancer Research· 0 citations
A patient-specific ex vivo organoid model is developed to define CXCL12/CXCR4-mediated immune regulation and identify additional cellular and molecular targets to enhance antitumor efficacy and demonstrate that CXCR4 inhibition enhances immune-cell infiltration and activation, modulates checkpoint expression, and promo...
I. Pellicciotta, G. Manji, A. Raufi et al.· Cancer Research· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.